ATUM

Executive Summary

ATUM is a US-based life sciences company specializing in synthetic biology, gene synthesis, protein expression, and cell line development. Founded in 2003, it operates as a one-stop biologics development partner, offering products, services, and technology licensing that enable researchers to go from a virtual sequence to a research cell bank. The company emphasizes a collaborative approach, combining client expertise with its in-house capabilities in machine learning, gene design, and protein engineering. By integrating these advanced tools, ATUM accelerates the development of biologics, including antibodies, enzymes, and other therapeutic proteins. Its long-standing presence in the industry and comprehensive platform position it as a key enabler for biotech and pharma companies seeking efficient and scalable solutions for drug discovery and development. Despite being private, ATUM's continued innovation in gene synthesis and protein optimization suggests a strong foothold in the growing synthetic biology market.

Upcoming Catalysts (preview)

• Q4 2026Launch of Enhanced Protein Expression Platform70% success
• 2027Strategic Partnership with Major Pharmaceutical Company50% success
• TBDExpansion into Gene Therapy Manufacturing Services40% success